Share:
REDWOOD CITY, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Dawn Svoronos as an independent member of Adverum s Board of Directors. Ms. Svoronos has three decades of global biopharmaceutical industry experience, spanning the United States, Canada, Europe, and Asia, gained during her 25-year career at Merck & Co. Dawn is a highly-esteemed industry veteran who brings extensive global commercial leadership experience to the board, said Laurent Fischer, M.D., chief executive officer of Adverum Biotechnologies. We have begun to build pre-commercial capabilities as we aim to advance ADVM-022 toward our first Phase 2b pivotal trial in mid-2021. Since ADVM-022 is in development for two large ocular disease indications, wet AMD and DME, it is critical to be prepared for global commercialization. Dawn will prov